TTO Seminar: Patenting Early-Stage Therapeutics
The CU Technology Transfer Office and Snell & Wilmer LLP present this free lunch-hour seminar, which will cover patent considerations for early-stage drug targets and compounds. Faculty entrepreneurs Rick Duke and Doug Graham will speak about their experiences in this field, and an attorney from Snell & Wilmer will discuss unique intellectual property concerns for these inventions.
About the Speakers:
Dr. Richard Duke is currently President and CEO of ApopLogic Pharmaceuticals, as well as the founder of GlobeImmune, Inc. He is an Associate Professor at the University of Colorado Health Sciences Center, and was TTO’s 2006 Business Advisor of the Year.
Dr. Douglas Graham is Chief Scientific Officer and a founder of Caveo Therapeutics. He is an Assistant Professor of Pediatrics and Immunology at the University of Colorado Health Sciences Center, and received TTO’s New Inventor of the Year award in 2005.
Laura Zeman of Snell & Wilmer is a registered patent attorney with a background in biology and physiology. She assists clients in creating, maintaining and enforcing their biotech and medical device patent portfolios. Her bio is available here.
Time & Place:
When: 12:00pm to 1:30pm on Wednesday, July 18.
Where: UCDHSC Anschutz campus, Research Complex 1, South Tower, 8th Floor (Room 8108).